GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Osang HealthCare Co 036220.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

5,260

+3.34%

Close of 5 Nov 2026, in KRW

About Osang HealthCare Co

Its shares trade on KOSDAQ under the ticker 036220.KQ. It has been listed since 13 March 2024. In the fiscal year to 31 December 2025, it reported revenue of ₩128.63bn and net income of ₩3.11bn. At that date it held total assets of ₩336.21bn and shareholders' equity of ₩281.06bn.

Osang Healthcare Co. Ltd. engages in the manufacture and sale of medical devices. The company is headquartered in Anyang, Gyeonggi-Do. The company went IPO on 2024-03-13. The firm produces blood glucose monitoring systems and bio sensors under the brand names of Healthpro, Glucolab, Finetest, Easygluco and others; hemoglobin A1c (HbA1c) analyzers and measuring sensors, which are blood glucose monitoring systems and consumables used in hospitals; cholesterol monitoring systems and measuring sensors under the brand name of Lipid-Pro, as well as pharmacy automation systems under the brand name of Autopharm. The firm was founded in 1996.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
13 Mar 2024
Website
osanghc.com ↗

Leadership

Pay as last reported

  • Mr. Dong Hyeon LeeChairman, since 2016
  • Cheol Hun KangPresident, Co-Chief Executive Officer, Director, since 2024
  • Byeong Yeol YooCo-Chief Executive Officer, Director, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Osang HealthCare's Healthpro blood glucose monitoring systems are widely used in Korean hospitals.
  • The company's Glucolab brand offers reliable HbA1c analyzers for diabetes management.
  • Autopharm pharmacy automation systems enhance efficiency in Korean pharmacy chains.

Weaknesses

  • Osang HealthCare's product range is limited to medical devices in Korea.
  • The company's brand names like Finetest and Easygluco lack global recognition.
  • Osang HealthCare has no presence in international markets beyond Korea.

Opportunities

  • Expanding HbA1c analyzers into the growing Asian healthcare market.
  • Increasing demand for Lipid-Pro cholesterol monitoring systems in Asia.
  • Potential partnerships with Korean hospitals for new medical device contracts.

Threats

  • Competition from established medical device manufacturers in Korea.
  • Regulatory changes affecting medical device approvals in Korea.
  • Economic downturns impacting hospital budget allocations for medical devices.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.